Factor X fusion proteins: Improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein
Mm. Guarna et al., Factor X fusion proteins: Improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein, PROT EX PUR, 20(2), 2000, pp. 133-141
Many recombinant proteins are synthesized as fusion proteins containing aff
inity tags to aid in the downstream processing. After purification, the aff
inity tag is often removed by using a site-specific protease such as factor
Xa (FXa). However, the use of FXa is limited by its expense and availabili
ty from plasma. To develop a recombinant source of FXa, we have expressed t
wo novel forms of FXa using baby hamster kidney (BHK) cells as host and the
expression vector pNUT. The chimeric protein FIIFX consisted of the prepro
peptide and the Gla domain of prothrombin linked to the activation peptide
and protease region of FXa, together with a cellulose-binding domain (CBDCe
x) as an affinity tag. A second variant consisted of the transferrin signal
peptide linked to the second epidermal growth factor-like domain and the c
atalytic domain of FX and a polyhistidine tag. Both FX variants were secret
ed into the medium, their affinity tags were functional, and following acti
vation, both retained FXa-specific proteolytic activity. However, the yield
of the FIIFX-CBDCex fusion protein was 10-fold higher than that of FX-CBDC
ex and other forms of recombinant FX reported to date. The FXa derivatives
were used to cleave two different fusion proteins, including a biologically
inactive alpha -factor-hirudin fusion protein secreted by Saccharomyces ce
revisiae. After cleavage, the released hirudin demonstrated biological acti
vity in a thrombin inhibition assay, suggesting that this method may be app
licable to the production of toxic or unstable proteins. The availability o
f novel FX derivatives linked to different affinity tags allows the develop
ment of a versatile system for processing fusion proteins in vitro. (C) 200
0 Academic Press.